Skip to main content
Premium Trial:

Request an Annual Quote

Roche to Distribute Prenosis Sepsis Software Solution

NEW YORK – Prenosis announced on Wednesday that it has entered into a distribution agreement with Roche to provide Prenosis' Sepsis ImmunoScore on Roche's digital platform.  

Under the agreement, the artificial intelligence-based Sepsis ImmunoScore will be available on Roche's Navify Algorithm Suite, which offers users algorithms from both Roche and third-party partners on one platform. The ImmunoScore uses laboratory-based biomarkers, clinical data, and AI to determine a patient's risk of having or developing sepsis within 24 hours of patient assessment, Chicago-based Prenosis said in a statement. The software is integrated into electronic medical records and generates a risk score for patients, assigning them to one of four specific risk stratification categories. 

The software received de novo marketing authorization from the US Food and Drug Administration last week.  

"The Navify Algorithm Suite seeks to offer a collection of algorithms that have undergone clinical validation by an expert medical and cross-functional team at Roche," Prenosis Cofounder and CEO Bobby Reddy said in a statement. "With the extensive market reach of Roche Diagnostics and ethical standards for AI-driven solutions, more hospitals and healthcare providers can take advantage of ImmunoScore, and its clinical utility in the fight against sepsis, in a responsible way."